Abstract |
N-(Phosphonacetyl)- L-aspartic acid, an inhibitor of aspartate transcarbamylase, was administered to 25 patients with advanced cancer by 10-minute infusion daily x 5 consecutive days to determine the toxicity and to look for evidence of therapeutic effect. Planned dose escalations ranged from 100 to 1250 mg/m2 (daily dose). Nausea, vomiting, and diarrhea were the most frequent toxic effects, with three of six patients treated at a daily dose of 1250 mg/m2 having severe diarrhea. Other toxic effects were encountered rarely and were not dose-limiting; these included mild leukopenia, thrombocytopenia, rash, stomatitis, and increases in SGOT. One patient with a widely metastatic carcinoid of unknown origin had an objective response lasting 6 weeks.
|
Authors | J S Kovach, A J Schutt, C G Moertel, M J O'Connell |
Journal | Cancer treatment reports
(Cancer Treat Rep)
1979 Nov-Dec
Vol. 63
Issue 11-12
Pg. 1909-12
ISSN: 0361-5960 [Print] United States |
PMID | 526923
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Organophosphorus Compounds
- Aspartic Acid
- sparfosic acid
- Phosphonoacetic Acid
|
Topics |
- Adult
- Aged
- Aspartic Acid
(analogs & derivatives, therapeutic use, toxicity)
- Bone Marrow
(drug effects)
- Carcinoid Tumor
(drug therapy)
- Diarrhea
(chemically induced)
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Organophosphorus Compounds
(therapeutic use)
- Phosphonoacetic Acid
(analogs & derivatives, therapeutic use, toxicity)
- Vomiting
(chemically induced)
|